JEMMA SMALL: Open Payments
NPI 1821462425 · KISSIMMEE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$418 in 15 payments from 8 companies in 2025. Trend: 2023 $241 · 2024 $95 · 2025 $418
Food & beverage: $418
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 1 | $122 |
| E.R. Squibb & Sons, L.L.C. | 4 | $76 |
| Teva Pharmaceuticals USA, Inc. | 3 | $70 |
| ABBVIE INC. | 2 | $54 |
| Supernus Pharmaceuticals, Inc. | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $15 |
Products named: INGREZZA, COBENFY, VRAYLAR, UZEDY, Qelbree, REXULTI, FANAPT, AUSTEDO XR.
Industry payments across FL — which companies pay providers there.
